Anna Rose Welch Headshot

Anna Rose Welch





Anna Rose Welch is the director of Cell & Gene Collaborative. In this role, she is forging close relationships with the leading voices and organizations in the cell and gene therapy manufacturing sphere. This includes establishing a peer group comprising Cell & Gene company manufacturing SMEs, conducting interviews and hosting interactive roundtables on the evolving manufacturing paradigm, and authoring thought leadership articles and blog posts via the Cell & Gene Collaborative blog.

Prior to launching Cell & Gene Collaborative, Anna Rose spent five years building an extensive network and editorial following as the Chief Editor of Biosimilar Development. In addition to penning thought leadership on biosimilar regulatory affairs, government policy, and commercialization advances, she was also an active participant in the biosimilar conferences circuit. She was appointed chair or served as a speaker and panel moderator at international conferences, including the World Biosimilar Congress USA, The Biotech Pharma Summit (EU), the CBI Biosimilars Summit, DIA Biosimilars Conference, and the Biosimilar Medicines Group Conference (EU). In 2018, she was invited to Brazil where she addressed members of the Brazilian Ministry of Health, ANVISA, and local biologics and biosimilar manufacturers on establishing national biologics and biosimilar policies. She also represented the publication on a media tour of Bangkok, Thailand in 2017, during which she reported on the country’s efforts to bolster its life sciences industry. In addition to writing for Biosimilar Development, she penned the introductory chapter to the book, Biosimilars: Regulatory, Clinical, and Biopharmaceutical Development (Springer, 2018).

In 2018, her first book of poetry, We, The Almighty Fires, was published by Alice James Books.

ARTICLES BY ANNA ROSE WELCH

  • From Manufacturing Floor To C-Suite: “Scaling Up” Cell & Gene Therapy Communication
    6/20/2022

    Though "communicate often" is a commonly offered best practice in the CGT space, it’s rarely discussed what this can and should look like, especially when it comes to elevating information from the manufacturing floor/team up to the C-Suite. My conversation with Mark Gergen, CEO of Poseida Therapeutics, however, gives us a great look of what this can look like for growing CGT companies.

  • Can USP, NIST, & NIIMBL Conquer The Biggest AAV Quality Challenge?
    5/18/2022

    As the CGT industry continues struggling to sufficiently characterize its AAV, USP's Fouad Atouf and I unpacked the ins-and-outs of this ongoing USP, NIST, and NIIMBL AAV quality initiative — as well as the CGT industry’s greatest needs from such a collaboration.

  • A Different Perspective On The Current C&G Manufacturing Capacity Constraints
    5/10/2021

    If you talk to anyone today about the decision behind constructing their own manufacturing facility, you’re likely to run into one of two big reasons spurring companies to make the investment in their own manufacturing footprint.

  • Two Tips On Navigating C&G Outsourcing Relationships In A Competitive Landscape
    5/4/2021

    It can be a bit overwhelming to keep tabs on all the movement occurring in the C&G industry today. You can’t open a newsletter or read an article without learning about company launches or acquisitions, clinical/manufacturing/regulatory milestones (or pitfalls), new partnerships, or facility ribbon cuttings/shutterings. While most of the glitzier headlines on C&G manufacturing highlight firms’ decisions to keep manufacturing in-house, outsourcing still plays — and will always play — a critical role in the development of these complex therapies.

  • How To Approach C&G Therapy Outsourcing In The Make Vs. Buy Era
    4/28/2021

    The world moves pretty fast — especially if you’ve been reading the many articles outlining the C&G industry’s feverish push to bolster and/or establish capacity.

  • C&G Therapy Manufacturing Automation: Making The Most Of Today’s Opportunities
    3/17/2021

    While the future for automation in the C&G manufacturing process will no doubt be bright, a conversation with this cell therapy executive also emphasized just how important cultivating talent and carefully analyzing supply chain costs will be in the automation puzzle before us.

  • Will It Be Biologics Business As Usual In 2021, Or Will Biosimilars Mean Business?
    1/20/2021

    In this fourth installment of the Editorial Board 2021 Outlook, it's clear that stakeholders are relying more heavily on biosimilars and that it’s more important than ever for biosimilar companies to keep carrying the torch for more competition, cost-savings, value, and responsible pricing.

  • The Biosimilar Toolbox: How To Ratchet Up Biosimilar Competition In 2021
    1/6/2021

    As you’ll read in the following responses, increased competition in 2021 is on the minds of many. How that competition unfolds has yet to be determined. But if one thing is clear, it’s that the industry has many exciting tools at its disposal to bolster biosimilar competition in 2021. 

  • The Top 5 Biosimilar Developments Of 2020
    12/30/2020

    Though 2020 felt like an endless descent into Dante’s Nine Circles of Hell, I wanted to end the year as I typically do: with a column highlighting the most important and positive biosimilar developments from the past 12 months.

  • Will These Big Biosimilar Questions Be Answered In 2021?
    12/23/2020

    Biosimilar Development is back with the highly anticipated second installment of its Editorial Board 2021 Outlook series! Here, the experts address the biggest questions they have going into 2021, as well as some of the events, policies, and corporate strategies they hope will help answer these questions.